The global custom recombinant protein production services market is estimated to be valued at US$ 4.9 billion in 2023 and is expected to exhibit a CAGR of 11.5% during the forecast period (2023-2030).
Analysts’ Views on Global Custom Recombinant Protein Production Services Market:
Rising funding and investment activities in the field of biotechnology are expected to drive growth of the custom recombinant protein production services market over the forecast period. For instance, On September 08, 2021, Aviva Systems Biology, a Biotechnology company, has announced the launch of its new Protein on Demand semi-custom recombinant protein portfolio for life scientists conducting basic research and preclinical studies. The Protein on Demand portfolio of over 300,000 proteins enables rapid access to small- to mid-scale production of customized proteins for research teams that struggle to find off-the-shelf solutions or find they do not meet the large-scale production requirements of custom protein expression suppliers.
Figure 1. Global Custom Recombinant Protein Production Services Market Share (%), By Expression System, 2023
To learn more about this report, request sample copy
Global Custom Recombinant Protein Production Services Market– Drivers
Figure 2. Global Custom Recombinant Protein Production Services Market Share (%), By Region, 2023
To learn more about this report, request sample copy
Global Custom Recombinant Protein Production Services Market- Regional Analysis
Among regions, North America is estimated to hold a dominant position in the global custom recombinant protein production services market over the forecast period. North America is estimated to hold 33.5% of the market share in 2023. The increasing adoption of inorganic strategies such as acquisitions and partnerships for the development of recombinant proteins by the key players in the market is expected to act as an opportunity for market growth over the forecast period. For instance, in August 2022, Orthofix US LLC, a medical device company, announced a strategic partnership agreement with CGbio, a developer of innovative, synthetic bone grafts for spine, orthopedic, trauma, and dental applications. As a part of this agreement, the two companies will work together for the clinical development and commercialization of Novosis recombinant human bone morphogenetic protein-2 (rhBMP-2) bone growth materials and other future tissue regenerative solutions for the Canadian and U.S. markets.
Global Custom Recombinant Protein Production Services Market– Impact of Coronavirus (COVID-19) Pandemic
The COVID-19 pandemic and lockdown in various countries across the globe have positively impacted the financial status of businesses across all sectors. The biotechnology sector is one such sector that has been heavily impacted by the pandemic.
However, governments of various countries are focusing on initiatives to fight against the COVID-19 pandemic and stop the spread of the coronavirus infection by implementing various measures in their countries. Countries such as the U.A.E., the U.K., and others have implemented some measures and guidelines to reduce the spread of COVID-19 in their countries. For instance, in December 2021, the Ministry of Health and Prevention (MoHAP) U.A.E. approved the emergency use of Sinopharm CNBG's (China National Biotec Group) new recombinant protein vaccine, following the strict monitoring and evaluation of the data of the study conducted in the U.A.E. The ministry affirmed that the emergency use of the new vaccine is in full compliance with the regulations and laws for a faster review of licensing procedures. This was a part of the ministry's painstaking efforts, in the cooperation with health authorities, to help in prevention of the COVID-19 pandemic among people.
Custom Recombinant Protein Production Services Market Report Coverage
Report Coverage | Details | ||
---|---|---|---|
Base Year: | 2022 | Market Size in 2023: | US$ 4.9 Bn |
Historical Data for: | 2018 to 2022 | Forecast Period: | 2023 to 2030 |
Forecast Period 2023 to 2030 CAGR: | 11.5% | 2030 Value Projection: | US$ 10.5 Bn |
Geographies covered: |
|
||
Segments covered: |
|
||
Companies covered: |
GenScript Biotech Corporation, SignalChem Biotech Inc., Crown Bioscience, Inc., BPS Bioscience Inc., Novoprotein, Applied Biological Materials (abm) Inc., Eurofins Pharma Discovery Services, Abgent (WuXi AppTec Company), OriGene Technologies, Inc., Kempbio, Inc., Trenzyme GmbH, Sino Biological Inc., Aragen Bioscience, a GVKBIO Company, LakePharma, Inc., Inc., Proteos Inc., Icosagen AS, Novus Biological LLC, Proteogenix, Premas Biotech, ATUM, and Aldevron |
||
Growth Drivers: |
|
||
Restraints & Challenges: |
|
Uncover macros and micros vetted on 75+ parameters: Get instant access to report
Global Custom Recombinant Protein Production Services Market Segmentation:
The global custom recombinant protein production services market report is segmented by expression system, by end user, and by region.
Global Custom Recombinant Protein Production Services Market- Cross Sectional Analysis:
Research institutes in the north america region are focused on the increasing establishment of new drug discovery institute, which are expected to drive market growth in the North America region. For instance, in November 2020, The University of Houston established the Drug Discovery Institute (DDI) with the goal of integrating new technologies such as artificial intelligence to streamline and modernize the drug discovery process. With an emphasis on multi-disciplinary collaborations to include the Texas Medical Center, DDI is focused on physical sciences to develop novel drugs for unmet medical needs, thus defining a new paradigm in academic drug discovery.
Global Custom Recombinant Protein Production Services Market: Key Developments
In July 2021, Atlas Antibodies, a provider of research antibodies based in Stockholm, Sweden, announced the acquisition of Evitria, a Biotechnology company. This transformative acquisition brings together a leading provider of highly validated research antibodies and a front-runner in the field of custom recombinant antibody expression.
In September 2021, Aviva Systems Biology, a company providing antibodies, immunoassay kits, and recombinant proteins for life science research, announced the launch of its new Protein on Demand semi-custom recombinant protein portfolio for life scientists conducting basic research and preclinical studies. The Protein on Demand portfolio of over 300,000 proteins allows rapid access to small- to mid-scale production of customized proteins for research teams.
Global Custom Recombinant Protein Production Services Market: Key Trends
Global Custom Recombinant Protein Production Services Market: Restraint
Global Custom Recombinant Protein Production Services Market - Key Players
Major players operating in the global custom recombinant protein production services market include GenScript Biotech Corporation, SignalChem Biotech Inc., Crown Bioscience, Inc., BPS Bioscience Inc., Novoprotein, Applied Biological Materials (abm) Inc., Eurofins Pharma Discovery Services, Abgent (WuXi AppTec Company), OriGene Technologies, Inc., Kempbio, Inc., Trenzyme GmbH, Sino Biological Inc., Aragen Bioscience, a GVKBIO Company, LakePharma, Inc., Inc., Proteos Inc., Icosagen AS, Novus Biological LLC, Proteogenix, Premas Biotech, ATUM, and Aldevron.
*Definition: Protein expression and purification play a central role in biochemistry. Recombinant proteins can be expressed using prokaryotic systems (E. coli and Bacillus subtilis), eukaryotic systems (yeast, insect cells, mammalian cells), or in vitro systems. A number of new strains, vectors, and tags have been developed in recent years to overcome the limitations of recombinant protein system, such as codon distortion, inclusion body formation, toxicity, protein inactivity, mRNA instability, and lack of post-translational modifications.
Share
About Author
Abhijeet Kale is a results-driven management consultant with five years of specialized experience in the biotech and clinical diagnostics sectors. With a strong background in scientific research and business strategy, Abhijeet helps organizations identify potential revenue pockets, and in turn helping clients with market entry strategies. He assists clients in developing robust strategies for navigating FDA and EMA requirements.
Missing comfort of reading report in your local language? Find your preferred language :
Transform your Strategy with Exclusive Trending Reports :
Frequently Asked Questions
Joining thousands of companies around the world committed to making the Excellent Business Solutions.
View All Our Clients